Investors are bracing for bigger declines ahead amid the rapidly changing macroeconomic conditions in the market.
Vice and HBO are announcing the most expansive content deal for either company.
Yemen is but a small producer of crude, so investors should not be overly concerned about the conflict, Francisco Blanch of Bank of America Merrill Lynch told CNBC.
The cockpit protocol at Germanwings will come under scrutiny as evidence emerges a pilot intentionally crashed Flight 9525, an aviation expert says.
CNBC's Phil LeBeau reports the latest details on what happened just before the crash of the Germanwings jet.
Ellen Pao’s lawsuit against her former employer, Silicon Valley VC firm Kleiner Perkins, is frivolous—and a setback for women, says Carol Roth.
For investors that can stomach the volatility, BlackBerry should be an attractive company in 2016, according to this analyst.
A robot may be your next family member.
Starbucks created the coffee industry, but there's room for new business models to compete against it, says Ed Schultz of Honolulu Coffee.
There are 11 stocks in the Standard & Poor's 500 that analysts are pretty much telling you to steer clear of. USA Today reports.
It seems like every celebrity has their own fragrance line these days. For $30,000, you can, too.
Swiss Re's report called the impact of low-rate dollar-cheapening policies "indisputable."
Oil surged Thursday on news that Saudi Arabia launched a military operation in Yemen, but analysts doubt geopolitical tensions will sustain the rally.
Richard Bernstein, Richard Bernstein Advisors, shares his thoughts on what's driving market volatility.
A recent bounce in oil from multiyear lows indicates prices have "probably bottomed," but that could hurt stocks, investor Dennis Gartman tells CNBC.
More financial advisors are attracting and building client relationships by tapping into emotional, social and other non-fiscal needs.
CNBC's Jim Cramer said analysts need to stop pushing SanDisk's stock amid its latest guidance cut.
Don't be emotional—be opportunistic. That's what two traders advise when it comes to playing the Nasdaq now.
A bipartisan compromise to overhaul Medicare bucks the popular impression that Washington can't accomplish anything at all.
Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.